🔗 Share this article

A daily slimming tablet could assist individuals cut their weight by up to a fifth, as per a study that might open doors for millions additional individuals to lose weight.

How the Drug Works

This medication, called the oral treatment, focuses on the identical GLP-1 pathways as slimming shots like tirzepatide and semaglutide. During research of over 3,000 adults, 20% of users who used the daily tablet for more than a year lost at least one-fifth of their body weight.

Slimming jabs are revolutionary, but oral forms represent a holy grail since they are easier to store, share and administer, and are also expected to be more affordable, offering fresh hope for millions attempting to lose weight.

The medication is a GLP-1 agonist, a type of drug that aids in lowering glucose levels, slows the breakdown of meals and may reduce appetite.

Trial Results and Accessibility

The weight loss observed in participants taking the tablet is not as stark as those among patients taking tirzepatide, but experts believe the tablet will be more accessible and user-friendly than injections.

Orforglipron has not been approved by the US Food and Drug Administration or health authorities in additional nations. The manufacturer has said it anticipates significant interest once the new pill is released.

In the study, the over three thousand participants were split into groups receiving orforglipron pills of varying strengths, whereas others took a dummy pill, for the trial period.

All of the volunteers had excess weight, indicating they had a body mass index reading of 30 or over, but they did not have diabetes. Participants from multiple nations were involved in the research.

Key Outcomes

Researchers discovered that after the study period people taking the lowest dose reduced an mean of nearly 8% of their weight. Those taking the maximum amount lost an mean of over 11% of their body weight.

Among users taking the highest doses, 54.6% had a reduction of 10% or more of weight, 36% had a loss of 15% or greater, and 18.4% had a reduction of 20% or more.

Researchers reported other health metrics also improved in participants using the drug, including better BP, a smaller waist size and a reduction in LDL levels.

The most common adverse reactions were stomach-related, which were said to be manageable.

“Among participants diagnosed with excess weight, 72-week use using the medication led to notable decreases in weight than placebo,” the authors wrote.

Potential Impact

Health experts have hailed slimming drugs as transformative. But injections come with additional logistical efforts for health services, so tablet forms might benefit many additional individuals aiming to lose weight.

Separate studies shows weight loss injections may be effective on children starting from age six who are obese or are diagnosed with diabetes. But, stomach problems were reported more frequently among young users taking the drugs.

They said that extended follow-up durations in future studies and additional practical research were “essential to establish the lasting impacts.”